Skip to main content

Table 4 Univariate and multivariate analyses for survival outcomes in patients who did not receive secondary debulking surgery

From: Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles

Characteristics Progression-free survival Overall survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR 95% CI aHR 95% CI P HR 95% CI aHR 95% CI P
Age at initial diagnosis, years
 ≥55 vs. <55 0.75 0.51–1.11 0.714 0.483–1.057 0.093 0.80 0.42–1.54    
Histologic type
 Non-HGSC vs. HGSC 1.01 0.54–1.91     0.75 0.23–2.45    
FIGO stage
 IV vs. I-III 1.14 0.74–1.73     0.94 0.44–2.00 0.74 0.33–1.64 0.461
Primary treatment strategy
 NAC vs. PDS 1.13 0.74–1.74     2.48 1.28–4.79    
Results of initial debulking surgery
 Residual tumor vs. CGR 1.15 0.79–1.68     1.22 0.63–2.34    
Platinum-free interval, months
 ≥12 vs. 6–12 0.44 0.29–0.65 0.40 0.27–0.61 <0.001 0.37 0.19–0.71 0.37 0.19–0.72 0.004
CA-125 at 1st recurrence, IU/mL
 ≥90 vs. <90 1.60 1.09–2.35 1.88 1.26–2.82 0.002 1.77 0.92–3.42 1.78 0.91–3.47 0.090
Residual tumor on CT after #6
 ≥1 cm vs. <1cm 1.12 0.76–1.63 1.23 0.84–1.81 0.294 1.79 0.91–3.52 2.10 1.05–4.22 0.036
CA-125 after #6, IU/mL
 ≥12.5 vs. <12.5 1.58 1.08–2.32 1.18 0.79–1.76 0.412 1.36 0.72–2.58    
Maintenance therapy
 Yes vs. No 0.48 0.30–0.77 0.44 0.26–0.72 0.001 0.69 0.29–1.66 0.71 0.29–1.76 0.456
Extended chemotherapy
 Yes vs. No 1.51 1.02–2.24 1.18 0.78–1.78 0.428 1.32 0.70–2.51 1.42 0.74–2.73 0.297
  1. Abbreviations: aHR Adjusted HR, CA-125 Cancer antigen 125, CGR Complete gross resection, CI Confidence interval, CT Computed tomography, FIGO International Federation of Gynecology and Obstetrics, HGSC High-grade serous carcinoma, HR Hazard ratio